Cinara Silva Feliciano1, Evangelina Inacio Namburete1, Jéssica Rodrigues Plaça2, Kamila Peronni2, Anzaan Dippenaar3, Robin Mark Warren3, Wilson Araújo Silva4, Valdes Roberto Bollela5. 1. Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Brazil. 2. Center for Medical Genomics, Clinics Hospital at Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Brazil. 3. DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa. 4. Center for Medical Genomics, Clinics Hospital at Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Brazil; Department of Genetics, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Brazil. 5. Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Brazil; Center for Medical Genomics, Clinics Hospital at Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Brazil. Electronic address: vbollela@fmrp.usp.br.
Abstract
BACKGROUND: The fast and accurate diagnosis of drug-resistant tuberculosis (DR-TB) is critical to reducing the spread of disease. Although commercial genotypic drug-susceptibility tests (DST) are close to the goal, they are still not able to detect all relevant DR-TB related mutations. Whole genome sequencing (WGS) allows better comprehension of DR-TB with a great discriminatory power. We aimed to evaluate WGS in M. tuberculosis isolates compared with phenotypic and genotypic DST. METHODS: This cross-sectional study evaluated 30 isolates from patients with detected DR-TB in Brazil and Mozambique. They were evaluated with phenotypic (MGIT-SIRE™) and genotypic (Xpert-MTB/RIF™, Genotype-MTBDRplus™, and MTBDRsl™) DST. Isolates with resistance to at least one first- or second-line drug were submitted to WGS and analyzed with TB profiler database. RESULTS: WGS had the best performance among the genotypic DST, compared to the phenotypic test. There was a very good concordance with phenotypic DST for rifampicin and streptomycin (89.6%), isoniazid (96.5%) and ethambutol (82.7%). WGS sensitivity and specificity for detection resistance were respectively 87.5 and 92.3% for rifampicin; 95.6 and 100% for isoniazid; 85.7 and 93.3% for streptomycin while 100 and 77.2% for ethambutol. Two isolates from Mozambique showed a Val170Phe rpoB mutation which was neither detected by Xpert-MTB/RIF nor Genotype-MTBDRplus. CONCLUSION: WGS was able to provide all the relevant information about M. tuberculosis drug susceptibility in a single test and also detected a mutation in rpoB which is not covered by commercial genotypic DST.
BACKGROUND: The fast and accurate diagnosis of drug-resistant tuberculosis (DR-TB) is critical to reducing the spread of disease. Although commercial genotypic drug-susceptibility tests (DST) are close to the goal, they are still not able to detect all relevant DR-TB related mutations. Whole genome sequencing (WGS) allows better comprehension of DR-TB with a great discriminatory power. We aimed to evaluate WGS in M. tuberculosis isolates compared with phenotypic and genotypic DST. METHODS: This cross-sectional study evaluated 30 isolates from patients with detected DR-TB in Brazil and Mozambique. They were evaluated with phenotypic (MGIT-SIRE™) and genotypic (Xpert-MTB/RIF™, Genotype-MTBDRplus™, and MTBDRsl™) DST. Isolates with resistance to at least one first- or second-line drug were submitted to WGS and analyzed with TB profiler database. RESULTS: WGS had the best performance among the genotypic DST, compared to the phenotypic test. There was a very good concordance with phenotypic DST for rifampicin and streptomycin (89.6%), isoniazid (96.5%) and ethambutol (82.7%). WGS sensitivity and specificity for detection resistance were respectively 87.5 and 92.3% for rifampicin; 95.6 and 100% for isoniazid; 85.7 and 93.3% for streptomycin while 100 and 77.2% for ethambutol. Two isolates from Mozambique showed a Val170Phe rpoB mutation which was neither detected by Xpert-MTB/RIF nor Genotype-MTBDRplus. CONCLUSION: WGS was able to provide all the relevant information about M. tuberculosis drug susceptibility in a single test and also detected a mutation in rpoB which is not covered by commercial genotypic DST.
Authors: V R Bollela; E I Namburete; C S Feliciano; D Macheque; L H Harrison; J A Caminero Journal: Int J Tuberc Lung Dis Date: 2016-08 Impact factor: 2.373
Authors: Timothy M Walker; Thomas A Kohl; Shaheed V Omar; Jessica Hedge; Carlos Del Ojo Elias; Phelim Bradley; Zamin Iqbal; Silke Feuerriegel; Katherine E Niehaus; Daniel J Wilson; David A Clifton; Georgia Kapatai; Camilla L C Ip; Rory Bowden; Francis A Drobniewski; Caroline Allix-Béguec; Cyril Gaudin; Julian Parkhill; Roland Diel; Philip Supply; Derrick W Crook; E Grace Smith; A Sarah Walker; Nazir Ismail; Stefan Niemann; Tim E A Peto Journal: Lancet Infect Dis Date: 2015-06-23 Impact factor: 25.071
Authors: Cinara Silva Feliciano; Lucas José Bazzo Menon; Livia Maria Pala Anselmo; Anzaan Dippenaar; Robin Mark Warren; Wilson Araújo Silva; Valdes Roberto Bollela Journal: ERJ Open Res Date: 2019-08-05
Authors: Emilyn Costa Conceição; Richard Steiner Salvato; Karen Machado Gomes; Arthur Emil Dos Santos Guimarães; Marília Lima da Conceição; Ricardo José de Paula Souza E Guimarães; Abhinav Sharma; Ismari Perini Furlaneto; Regina Bones Barcellos; Valdes Roberto Bollela; Lívia Maria Pala Anselmo; Maria Carolina Sisco; Cristina Viana Niero; Lucilaine Ferrazoli; Guislaine Refrégier; Maria Cristina da Silva Lourenço; Harrison Magdinier Gomes; Artemir Coelho de Brito; Marcos Catanho; Rafael Silva Duarte; Philip Noel Suffys; Karla Valéria Batista Lima Journal: Mem Inst Oswaldo Cruz Date: 2021-03-15 Impact factor: 2.743
Authors: Evangelina Inacio Namburete; Anzaan Dippenaar; Emilyn Costa Conceição; Cinara Feliciano; Margarida Maria Passeri do Nascimento; Kamila Chagas Peronni; Wilson Araújo Silva; Josefo João Ferro; Lee H Harrison; Robin Mark Warren; Valdes Roberto Bollela Journal: Tuberculosis (Edinb) Date: 2020-01-29 Impact factor: 2.973
Authors: Bugwesa Z Katale; Peter M Mbelele; Nsiande A Lema; Susana Campino; Stephen E Mshana; Mark M Rweyemamu; Jody E Phelan; Julius D Keyyu; Mtebe Majigo; Erasto V Mbugi; Hazel M Dockrell; Taane G Clark; Mecky I Matee; Stellah Mpagama Journal: BMC Genomics Date: 2020-02-21 Impact factor: 3.969